Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC
BA3361, a NextGen CAB ADC Targeting Nectin4
Updated Phase 1 and preliminary Phase 2 results from a study of evalstotug (BA3071), an anti–CTLA-4 conditionally active biologic, with or without nivolumab, in advanced solid tumors
Evalstotug (BA3071): A potent conditionally active biologic (CAB) anti–CTLA-4 antibody designed to enable high exposures, extended dosing, and reduced immune-mediated toxicity.
Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Phase 1 Study of Evalstotug (BA3071), an anti–CTLA-4 Conditionally Active Biologic, in Combination with Nivolumab in Advanced Solid Tumors
Novel Conditionally Active Tetravalent B7-H3 x CD3 T-cell Engagers Targeting Solid Tumors
First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case Report
Conditionally Active Biologic (CAB) ADCs with Novel NextGen Linker Show Improved Efficacy and Safety
Novel Conditionally Active Biologic Tetravalent T-Cell Engagers Targeting Solid Tumors
